HPO, in Collaboration with Eastman, Announces Upcoming Launch of High Energy Visible Light Filtering Film in the Transportation Space
March 16, 2023 10:15 AM Eastern Daylight Time
CHARLOTTE, N.C.–(BUSINESS WIRE)–Eastman and High Performance Optics, Inc. (HPO) announced today that a selective High Energy Visible Light (HEVL) filtering window film for the transportation industry will be launched in Asia. Selective HEVL filtering has been the optimal solution in filtering undesirable “blue light” from human eyes in various applications such as eyeglasses, over-the-counter readers, prescription contact lenses and screen shields. Under a license agreement, Eastman is launching LLumar® AIR BLB and LLumar® ATR BLB window films using HPO’s patented selective HEVL (blue light) filtering technology. The launch is planned for February 2023 in China.
“Our purpose at Eastman is to enhance the quality of life in a material way”Tweet this
In the development process, HPO partnered with Frontier Specialty Chemicals (Frontier), who specializes in research, analytics, customization, and organic design of custom chemistry for various industries around the world. For this new product launch, Frontier worked side by side with Eastman in the custom development of this solution. Years in the making, HPO, Frontier, and Eastman have been testing and modifying the chemistry to bring this product to market, with the goal of providing HEVL protection for millions around the world.
“From day one, HPO’s goal has been the protection of the human retina from the undesirable effects of blue light. HPO has worked to identify mediums that allow our company to put protective filters between the human eye and the sources of HEVL. Eastman’s launch of a selective HEVL filtering film in the transportation space is one more huge step in our mission. HPO has been working for years, with some of the best companies in the world, to protect consumers from HEVL emitted from electronic devices. Sun light emits 10-100X more undesirable HEVL (blue light), on a cloudy day, than electronic devices. Now, Eastman will be the first to offer selective HEVL filtering of undesirable blue light from the sun, in the auto transportation space. We are excited and proud of the work that has been completed by Eastman, Frontier and HPO. We have collaboratively worked together to bring a solution forward that can now offer protection for millions within a new medium, the auto transportation space,” said Larry Rodriguez, Chief Executive Officer of HPO.
“Our purpose at Eastman is to enhance the quality of life in a material way,” said Erin Bernhardt, vice president and general manager of Eastman Performance Films business. “The collaboration with HPO is another step in doing that through innovation that filters harmful blue light from the sun’s visible spectrum to protect the driver and passenger vision with blue-light filtering window films. We’re excited to launch this new product-line into the China market where there is leading awareness of the impact of unfiltered blue light from the sun.”
HPO was founded in 2006 by Dr. Andy Ishak, OD, FAAO. Dr. Ishak was one of the early drivers of protection for the human retina from HEVL. HPO’s first application opportunities were in the ophthalmic space where HPO has now licensed its Intellectual Property (IP) and Technology to some of the largest companies in the world within their respective application spaces. Products using HPO’s IP and technology now offer protection for millions around the world from undesirable HEVL. https://hpousa.com/press/
HPO is a world leader in driving the need for HEVL protection for the human eye and has patented, licensed, and developed custom technology solutions for some of the largest companies in the world for eyeglasses, contact lenses, readers, screen shields for electronic devices and now transportation/ automotive window films. HPO has over 100 issued or pending patents on Selective HEVL (Blue Light) Filtering. HPO IP – HPO USA
Founded in 1920, Eastman is a global specialty materials company that produces a broad range of products found in items people use every day. With the purpose of enhancing the quality of life in a material way, Eastman works with customers to deliver innovative products and solutions while maintaining a commitment to safety and sustainability. The company’s innovation-driven growth model takes advantage of world-class technology platforms, deep customer engagement, and differentiated application development to grow its leading positions in attractive end markets such as transportation, building and construction, and consumables. As a globally inclusive and diverse company, Eastman employs approximately 14500 people around the world and serves customers in more than 100 countries. The company had 2022 revenues of approximately $10.6 billion and is headquartered in Kingsport, Tennessee, USA.
About Frontier Specialty Chemicals
Founded in 1975, Frontier Specialty Chemicals (Logan, Utah) is a chemical manufacturer specializing in organic synthesis. Frontier has specialized expertise in porphyrin synthesis, organoboron and custom synthesis. Frontier’s scientific team is devoted to discovering and developing applications of novel materials for use in the medical and material science fields. Frontier works closely with organizations to customize and develop unique materials for their applications and manufacturing processes.
Frontier Specialty Chemicals develops and provides process to produce active pharmaceutical
ingredient for clinical trial of COVID-19 therapeutic investigational drug RBT-9
June 23, 2020 | Press Release
―Renibus Therapeutics Will Conduct Phase 2 Trial of Compound with Antiviral and
Immune-Modulating Activity to treat effects of COVID-19 ―
Logan, UT – June 23, 2020 – Frontier Specialty Chemicals, a world leader in porphyrin chemistry and chemical
building blocks for drug discovery and material science research, today announced their collaboration
with Renibus Therapuetics to develop a therapeutic for COVID-19. Frontier Specialty Chemicals identified and
developed multiple synthetic processes to produce stannous protoporphyrin (SnPP) – the active
pharmaceutical ingredient of RBT-9, an investigational drug entering a Phase 2 trial for the treatment of
COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as
kidney or cardiovascular disease. RBT-9, which has been awarded Fast Track designation by the U.S.
Food and Drug Administration (FDA), has demonstrated both antiviral and immune-modulating activities
in preclinical studies.
RBT-9 is being developed by Renibus Therapeutics as an antiviral agent with organ-protective attributes.
With the advent of the coronavirus pandemic, Renibus scientists moved quickly to plan and initiate a
clinical trial of RBT-9 in COVID-19 patients. They chose Frontier Specialty Chemicals to develop a scalable process
with robust chemical techniques allowing RBT-9 to be produced under cGMP protocols for use in human
clinical trials, said Dustin Cefalo, PhD, VP of Porphyrin Chemistry at Frontier Specialty Chemicals.
Al Guillem, CEO, of Renibus stated, “Renibus Therapeutics Inc., is pleased to be partnering with Frontier
Specialty Chemicals on the manufacturing and supply of RBT-9 for study REN-005 “A Phase 2, Randomized,
Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Preventing Progression of COVID-19 in
High-Risk Individuals.” Frontier Specialty Chemicals ability to quickly react and support our clinical study efforts
during these critical times is a testament to their commitment to deliver superior service and support to
Upon development of the synthetic process for production of SnPP, Frontier Specialty Chemicals transferred their
processes and know-how to an outside GMP facility for production of the active pharmaceutical ingredient
for Renibus Therapeutics. Frontier Specialty Chemicals continues to provide technical consultation and problem solving
expertise to Renibus Therapeutics with regards to production of SnPP and support the continued
development of RBT-9 as a promising therapeutic for the treatment of Covid-19.
About Renibus Therapeutics and RBT-9 : Renibus Therapeutics is developing a novel anti-viral
therapy, RBT-9 (stannous protoporphyrin–SnPP), for the treatment of COVID-19 in early stage patients
who are asymptomatic or mildly symptomatic and at high risk for disease progression. Renibus is
investigating the ability of RBT-9 both to inhibit viral activity and to prevent organ failure in COVID-19
patients. For more information visit https://renibus.com/#contact.
About Frontier Specialty Chemicals: Frontier Specialty Chemicals specializes in research and development, custom
synthesis, process development, scale-up, and quality manufacturing of specialized compounds and fine
chemicals. Our skilled chemists have developed compounds for use in drug discovery, FDA approved
medical devices, and in chemical and life sciences research. It has been our philosophy for over 40 years
that innovative solutions and accountability to our clients are key components of successful custom
research projects. We view quality as a guiding principle, achieved by rigorous scientific diligence at each
step of the development and manufacturing process. Frontier Specialty Chemicals is headquartered in Logan, UT.
For more information, visit https://frontierspecialtychemicals.com. Contacts: Frontier Specialty Chemicals, Inc: email@example.com, 1-435-753-1901